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ABSTRACT.   
 Driven by the communication of dopamine, the vertebrate reward system has been 
evolutionarily conserved to maintain survival and optimize fitness.  The neural circuits governing this 
system integrate sensory stimuli to produce appropriate, self-preserving responses that underlie 
experience-based learning.  In the most primitive vertebrates, dopamine release in neuronal circuits 
drives homeostatic behaviors, such as seeking nutrients, finding a mate, or avoiding danger.   From 
agnathans to mammals, dopaminergic synthesis and signaling genes and molecules, along with neuronal 
pathways and reward system-based behaviors, remain highly conserved.  Dopamine signaling proteins 
include two classes of metabotropic G-Protein Receptor Coupled Dopamine Receptors, D1-like (DRD1) 
and D2-like (DRD2).  DRD1 stimulate the neuron by upregulating adenylate cyclase activity, while DRD2 
inhibits neurons by blocking or down-regulating adenylate cyclase.  Though greatly conserved, the 
reward system can be hijacked by chemicals that trigger the release of dopamine.  Drugs of abuse, like 
amphetamines, for instance, increase dopamine availability to trigger reward circuits, leading to 
addiction behaviors. The mechanisms by which amphetamines stimulate dopamine release among 
reward neurons and the addiction behaviors expressed have not yet been modeled and correlated in 
zebrafish, a viable translational model for studying drug addiction.  In the present study, addictive 
behaviors in zebrafish were elicited after fish were exposed to amphetamines through a condition place 
preference paradigm.  After the conditioning period, amphetamine-treated fish spent significantly more 
time in an experimental tank compartment that was paired with amphetamine exposure (p = 0.0031).  
Likewise, THC (p = 0.0393) and the anesthetic, MS222 (p = 0.0290) significantly affected time spent in 
the non-preferred tank compartment after conditioning.  Amphetamine-treated fish also displayed 
unique and heightened anxiety and vigilance behaviors.  These behaviors and the influence of 
amphetamines on conditioned learning are likely stimulated by the increased expression of DRD1 
receptors measured in dopaminergic brain areas in the fish compared to controls. These data support 
the hypothesis that drugs of abuse like amphetamines trigger the communication of dopamine among 




Chapter 1:  Introduction 
 
 Addiction continually creates substantial economic, health and societal costs, but 
available treatments remain inadequate for most individuals [1]. By analogy with other medical 
disorders, an improved understanding of the biological basis of addiction will lead to more 
effective treatments and eventually to cures and preventative measures. According to the 
National Institute on Drug Abuse (NIDA), addiction is defined as a chronic, relapsing brain 
disease characterized by compulsive drug seeking and use, despite harmful consequences. This 
implies that the ‘addicted-state’ is not triggered instantaneously upon exposure to drugs of 
abuse. Rather, repeated exposure produces neuroadaptations (neuroplastic changes) that 
contribute to pathological drug-related behaviors [2]. These include long-term alterations in 
gene expression, protein regulation, anatomy, and synaptic function that collectively influence 
the neural circuits that govern reward, motivation, and higher order cognitive control to 
produce maladaptive behaviors [1,3].  
Although the brain circuitry underlying addiction is complex, it is clear that the 
mesolimbic dopamine system, consisting of the ventral tegmental area (VTA) and nucleus 
accumbens (NAc), are crucial substrates for the neural adaptations that underlie addiction [4,5,6]. 
Despite the chemical diversity and individual molecular targets, all addictive drugs directly or 
indirectly increase dopamine (DA) concentration in projections to the VTA as well as within the 
VTA itself [6]. The drug-induced plasticity observed can be explained by ‘the learning rule’ 
proposed by Canadian psychologist Donald Hebb, stating that when two neurons are in close 
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enough proximity for one to excite the other, the influence of repeated stimulation of one cell 
by the other will promote growth or change to increase the efficiency of communication 
between neurons [7].  
The phenomenon described by Hebb is commonly referred to as long-term potentiation 
(LTP). Two phases of LTP have been identified: early-LTP (E-LTP; short term memory) and late-
LTP (L-LTP; long term memory). Current thinking posits that the efficacy of a synapse can be 
influenced either by altering the amount of neurotransmitter released by the pre-synaptic 
neuron or by changes in receptor density on the post synaptic neuron [1,4,8]. Since all addictive 
drugs influence pre-synaptic release of DA, an explanation for the synaptic dysfunction in these 
circuits could potentially be explained by changes in the post-synaptic neuron [9]. In this 
context, the neurotransmitter receptors poised to influence synaptic transmission are likely to 
play critical roles in the effects of abused drugs and as novel therapeutic targets. 
 Under normal conditions, the mesolimbic reward system controls an individual’s 
response to natural rewards, such as food, sex, and social interactions, and is therefore an 
important determinant of motivation and incentive drive. In simplistic terms, activation of this 
pathway tells the individual to repeat what it just did to get that reward [10,11]. Additionally, 
synapses communicate with areas of the brain associated with memory to pay particular 
attention to all features of that rewarding experience, so it can be repeated in the future. 
Communication among reward nuclei, Ventral Tegmental Area (VTA), Nucleus Accumbens 
(NAc), and prefrontal cortex (PC), is mediated through dopaminergic (DAergic) neurons that are 




Within the VTA, there are two general populations of GABAergic neurons: interneurons, 
which provide local inhibition of DA neurons; and projection neurons, which provide long-range 
inhibition of multiple brain areas including the NAc [14-17]. Once stimulated, GABAergic spiny 
neurons release the inhibitory neurotransmitter γ -aminobutyric acid (GABA), which interacts 
with GABA receptors present on presynaptic DA neurons [18]. Binding of GABA to ionotropic 
GABA receptors causes a conformational change to the membrane receptor protein, resulting 
in an influx of Cl- ions and hyper polarization of presynaptic DA neuron [19]. In this case, the 
hyper polarization event creates a more negative cell membrane potential, thus inhibiting 
neuronal firing and DA release [20,21]. Without GABA signaling modulating DAergic neurons, DA 
is released into the synapse, binds to postsynaptic DA receptors (DAr), and through various 
intracellular signaling mechanisms alters normal gene expression that potentially influences 
neuronal structure and communication between neighboring neurons [22,23]. In general, 
inhibition is critical for regulating neuronal excitability, and allows flexibility in circuit 
connectivity.  
The rewarding effect of addictive drugs is also mediated by mesolimbic DA. Following 
exposure to drugs of abuse, DA is elevated throughout the mesolimbic system [24]. Drugs of 
abuse modulate release of DA through different mechanisms such as blocking GABA vesicle 
release, competitive binding of GABA receptor, inhibiting DA reuptake, and influencing vesicle 
release of DA [25]. In particular, the psychoactive drugs amphetamine (AMPH) and Δ⁹-
tetrahydrocannabinol (THC) exert their rewarding and reinforcing effects by elevating 
extracellular DA and prolonging DAr signaling via direct or indirect interaction with DAergic 
neurons, respectively (Figure 1) [24,25]. AMPH has been characterized as a DA releaser that 
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elevates DA by four major mechanisms: 1) It is a substrate for the DA transporter (DAT) that 
competitively inhibits DA uptake, 2) It facilitates the movement of DA out of vesicles and into 
the cytoplasm, 3) It promotes DAT-mediated reverse-transport of DA into the synaptic cleft 
independently of action-potential-induce vesicular release, and 4) It inhibits GABA receptor-
evoked hyperpolarization via competitive binding to GABA receptors on the presynaptic 
DAergic neuron [26-30].  
Different from AMPH, THC promotes DA release indirectly through binding of 
cannabinoid receptors (CB1, CB2) present on GABAergic neurons, leading to a cascade of 
molecular reactions that reduces GABA vesicle release, thus allowing for DA release from the 
presynaptic DAergic neurons [25]. This persistent increase in DA results in pathological incentive 
motivation to drug-associated cues and drug addiction. In this way, drug addiction is an 
example of adverse behavioral consequences arising from a malfunction in the mesolimbic 
system [14].  
The differential mechanisms by which drugs of abuse alter reward system signaling 
critically depends on the interaction of these drugs with neurotransmitter receptors within the 
mesolimbic circuit [5,14]. The main type of receptor is DAr, belonging to the class of G protein-
coupled receptors (GPCRs), whose actions modulate the communication of DA that underlies 





Figure 1: The mesocorticolimbic dopamine system as target of addictive drugs 
Sagittal slice of neural tissue illustrating the ventral tegmental area (VTA), the nucleus accumbens (NAc) and the 
prefrontal cortex (PFC). The projecting neurons are mostly dopaminergic, and under inhibitory control of GABA 
neurons. Schematic illustrates three cellular mechanisms by which addictive drugs increase mesolimbic DA levels. 
Nicotine can directly depolarize DA neurons, while opioids, gamma-hydroxybutyric acid (GHB), benzodiazepines 
and cannabinoids act indirectly by inhibition of GABA neurons. Cocaine, amphetamines and ecstasy interact with 
DA transporter on axon terminals and dendrites of DA neurons. Cocaine acts as an inhibitor of DA transporter, 
while amphetamines and ecstasy promote non-vesicular release of DA. Both mechanisms result in an increase of 




 Dopamine Receptors 
 
 G protein-coupled receptors (GPCR) constitute the largest family of membrane proteins 
and mediate most general cellular responses to hormones and neurotransmitters, as well as 
being responsible for key physiological and metabolic functions [1,5,31]. At the most basic level, 
all GPCRs are characterized by the presence of seven membrane-spanning α-helical segments 
separated by alternating intracellular and extracellular loop regions that couple to 
heterotrimeric G proteins [31,32]. GPCRs in mammals are classified into five main families 
according to the GRAFS classification: glutamate, rhodopsin, adhesion, frizzled, and secretin [33]. 
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The rhodopsin family is the largest, serving as molecular targets for the neurotransmitters 
serotonin, DA, norepinephrine, epinephrine, histamine, and acetylcholine [31,32]. Upon ligand-
activation of GPCR, the heterotrimeric G protein dissociates into α and βγ subunits. The 
activated G proteins can then transduce and amplify GPCR signals via secondary messengers to 
elicit a variety of cellular responses [1,31-33] (Figure 2). The cAMP-dependent pathway, also 
known as the adenylyl cyclase (AC) pathway, is an example of a secondary messenger system 
involved in signal transduction. GPCRs are often classified by the G protein α subunits with 
which they prefer to interact and are represented as either Gs (stimulatory) or Gi (inhibitory) 
[34]. In a cAMP-dependent pathway, the activated Gsα subunit binds to and activates an enzyme 
called adenylyl cyclase, which in turn catalyzes the conversion of ATP into cyclic adenosine 
monophosphate (cAMP). Increases in concentration of cAMP may lead to the activation of 
protein kinase A (PKA), also known as cAMP-dependent kinase [30,34]. As a result, PKA 
phosphorylates additional downstream target proteins, some of which are capable of being 
transported to the nucleus to bind to sequence specific sites and initiate synapse modifying 
transcriptional events [35]. In the case of Giα, the opposite is observed. Giα mainly inhibits the 
cAMP dependent pathway by preventing adenylyl cyclase activity [34,35]. Thus, a decreased 
production of cAMP from ATP, resulting in reduced intracellular concentrations of active PKA. 
As mentioned previously, drugs of abuse, in essence, hijack the brain’s reward system and 
mediate the abnormal release of DA and its exclusive activation GPCR dopamine receptors. 
In the brain, DA transmits synaptic information by binding to specific cell surface GPCRs. 
As members of the GPCR superfamily, DAr have a canonical seven transmembrane structure 
and can signal through both G protein-dependent and –independent mechanisms [31,32]. To 
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date, five subtypes of DAr have been identified and cloned. Based on their structural and 
pharmocological properties, a general subdivision into two groups of receptors has been made: 
D1-like (D1, D5) and D2-like (D2, D3, D4) [1,5,36-41]. Within the mesolimbic reward pathway, the 
two receptor classes exert opposing intracellular effects via their associated heterotrimeric 
GTP-binding proteins (G proteins). D1-like receptors couple to Gs family of G proteins to 
stimulate cAMP production by AC and are found exclusively postsynaptically on DA-receptive 
cells, whereas D2-like receptors inhibit AC via Gi signaling and are present both on pre- and 
postsynaptic neuron [1,5,40]. D1-like and D2-like receptors are further distinguished on the basis 
of differential protein structure and topology of genetic sequences, distinct effector 
mechanisms, and distribution patterns within the CNS [42].  
 
Figure 2: Signaling mechanisms and neuronal effects of dopamine receptors 
DA receptors are GPCRs and are subdivided into D1-like (D1 and D5) and D2-like (D2, D3, and D4). D1-like receptors 
are coupled to Gαs, which activates AC, leading to the production of cAMP and activation of PKA, which 
phosphorylates several downstream substrates. D1-like receptors increase exciteability and firing to promote LTP 
of striatal medium spiny neurons. D2-like receptors are coupled to Gαi, which inhibit the AC-cAMP-PKA 




The D1- and D2-classes of DAr are different at the level of genetic structure, primarily in 
the presence of introns in their coding sequences [36]. The D1 and D5 receptor genes do not 
contain introns in their coding regions, but the genes that encode the D2-like receptors have 
several introns, with six introns found in the gene that encodes the D2 receptor, five in the 
gene for D3 receptor, and three in the gene for D4 receptor [36,43,44]. The existence of introns 
present in the genetic organization of D2-like receptors provides the basis for the generation of 
receptor splice variants [40]. For example, the D2 receptor exists in two main variants, the long 
isoform (D2L) and the short isoform (D2S), generated by alternative splicing of an 87-base-pair 
exon between introns 4 and 5 [36]. These two isoforms differ in the presence or absence of 29 
amino acids in the third intracellular loop. These D2 receptor variants exhibit distinct 
anatomical, signaling, and pharmacological properties. D2S has been shown to be mostly 
expressed presynaptically and to be involved in autoreceptor functions such as control of 
dopamine release and regulation of extrasynaptic dopamine levels, whereas D2L is 
predominantly a postsynaptic isoform [36,45,46].  The D1 receptors having no intron allows for all 
members of the gene family to be isolated rather easily from genomic DNA. In mammals, two 
receptor subtypes were identified (D1A/D1, D1B/D5), but other subtypes exist in 
nonmammalian vertebrates; D1c (Xenopus), D1D (chicken), and D1X (teleost). These additional 






Sequence and Topology 
 The individual members of the subfamilies of D1- and D2-like receptors share a high 
level of homology of their transmembrane domains and have distinct pharmocological 
properties [43,44]. D1 and D5 receptors share an 80% homology in their transmembrane domain, 
whereas D2 receptors share a 75% homology with D3 and a 53% homology with the D4 
transmembrane domains [43]. The N-terminal domain of all receptor subtypes have a similar 
number of amino acid residues and carries a variable number of consensus N-glycosylation sites 
[49].  Electron density studies identified D1-like receptors to have short third intracellular loops 
and long carboxyl terminal tails, whereas the D2-like receptors have long third intracellular 
loops and short carboxyl terminal tails [36,43,49] (Figure 3). The difference observed in the third 












CNS Distribution  
 DAr have broad expression patterns in the brain and in the pheriphery. The D1 and D2 
receptors are present in all of the known target areas of DA in the CNS of vertebrates and their 
expression territories exhibit considerable overlap. However, neurons do not express D1 and 
D2 receptors simultaneously (or at best, only at very different levels), revealing that the 
transcriptional regulation of the two dopamine receptor classes is essentially non redundant 
[42]. A summary of this tissue distribution is given in Table 1. The D1 receptors are expressed at 
high density in the nigrostriatal, mesolimbic, and mesocortical areas, such as the caudate-
putamen (striatum), NAc, substantia nigra, olfactory bulb, and frontal cortex. In these areas of 
the reward system, binding of D1 receptors modulates feelings of reward and pleasure, 
motivational aspects of movement, experiential and reinforced learning, olfactory stimulus 
integration, and long-term memory.  In the NAc, the outer layer or shell contains high 
populations of both D1 and D2 receptors and is most heavily influenced by drugs of abuse. D1 
receptors in the shell of the NAc mediate reinforced learning and cognition associated with 
pleasurable experiences. D5 receptors are expressed at low levels in multiple brain regions, 
including pyramidal neurons of the prefrontal cortex, substantia nigra, hypothalmus, 
hippocampus, and the dentate gyrus, likely aiding in some of the reward functions, but also 
playing a part in episodic memory, reasoning, moderation of emotion, and satiety. The highest 
level of D2 receptors are found in the substantia nigra, olfactory bulb, caudate and putamen, 
VTA, and NAc. Activation of D2 receptors mediate similar mechanisms of reward and learning 
as D1 receptors, however D2 receptors in the NAc mediate cognition associated with aversive 
stimuli. The D3 receptors have a more limited pattern of distribution, the highest level of 
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expression being observed in the limbic areas, such as the shell of the NAc and the olfactory 
tubercle, likely pairing motivation/drive with reward, reward with emotion, and operant 
learning. The D4 receptor has the lowest level of expression in the brain, with documented 
expression in the frontal cortex, amygdala, hippocampus, hypothalmus, thalmus, and 
substantia nigra, uniquely contributing to novelty seeking behaviors (curiosity, exploration), 











Dopamine Receptor Function 
 The D1- and D2 like receptor classes differ functionally in the intracellular signaling 
pathways they modulate. The D1-like receptors are coupled to heterotrimeric Gαs-proteins, 
with activation leading to increase AC activity, and increased cyclic AMP (cAMP) production. 
This pathway induces the activation of PKA, resulting in the phosphorylation of variable 
substrates and the induction of immediate early gene expression, as well as the modulation of 
Receptor Location 
D1 Nigrostriatal, mesolimbic, and mesocortical areas, such as the caudate-putamen 
(striatum), Nac, substantia nigra, olfactory bulb, and frontal cortex 
D2 Substantia nigra, olfactory bulb, caudate putamen, VTA, Nac 
D3 Olfactory bulb, NAc 
D4 Substantia nigra, hippocampus, amygdala, thalmus, hypothalmus, frontal cortex 
D5 
pyramidal neurons of prefrontal cortex, substantia nigra, hypothalmus, 
hippocampus, and dentate gyrus 
      
                      Table 1: Summary of dopamine receptor locations 
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numerous ion channels. In contrast, D2-like receptors are coupled to Gαi-proteins and 
negatively regulate the production of cAMP, resulting in decreased PKA activity, activation of 
ionotropic K+ channels, and the modulation of other ion channels [30-33].  
 The signaling pathways and gene expression changes associated with various DA 
receptors have been suggested to play a critical role in drug-induced neuro-adaptations in the 
brain (Figure 4). The mechanisms by which drugs of abuse (e.g. amphetamine and THC) are able 
to induce addiction vary considerably; nonetheless, similarities exist [25,51]. Stimulation of 
DAergic neuron by drugs of abuse induces the phosphorylation of cAMP-response element 
binding protein (CREB) and the transient expression of immediate early genes (IEGs) including c-
Fos, Jun, and ΔFosB [52]. The transcription factor ΔFosB has been found to be a remarkable 
molecular biological mediator for addiction [53]. ΔFosB is a member of the Fos family 
transcription factors, which dimerize with a member of the Jun family to form activator protein-
1 (AP-1) transcription factor complexes. AP-1 complexes then bind to AP-1 consensus 
sequences (TGAC/GTCA) present in the promotor regions of many neural genes. In contrast to 
all other Fos family proteins and IEGs, ΔFosB presents an unusually high degree of stability and 
therefore has a conspicuously longer half-life. To date, several downstream target genes for 
ΔFosB have been identified to be involved in the molecular pathways concerning addictive 






Figure 4: Regulation of gene expression by dopamine 
 
Stimulation of dopamine receptors in striatal neurons activates secondary messenger cascades that induce gene 
expression. Some genes are responsible for homeostatic adaptations that reduce sensitivity to subsequent 
stimulation; while others are involved in altering the strength of specific synaptic connections{25]. 
 
 
Zebrafish: A versatile addiction model? 
 
Organism survival often depends upon learning the conditions necessary to acquire 
naturally rewarding and reinforcing stimuli that serve homeostatic, survival, and reproductive 
purposes. Animals rapidly learn these behavioral responses to obtain natural rewards and can 
identify the environmental cues that predict them. Additionally, learning occurs following the 
consumption of rewarding psychoactive substances, such as amphetamine and THC [56,57]. Rapid 
conditioning occurs when drug use is paired with a place, thing, or emotional state, primarily 
due to the nature of reward circuitry within the limbic system [58]. Exposure to cued stimuli may 
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induce cravings for the drug in individuals that are dependent on a substance, and even in 
those who have been abstinent from drug use for a period of time [59]. These classical Pavlovian 
and operant learning processes are believed to mediate the transition from casual, voluntary 
drug use, to more habitual and compulsive behaviors [60]. Rats and mice have been the pioneer 
organism in addiction research, due to the anatomical, biological and genomic homology 
between rodents and humans. However, use of rodent models are burdened by challenging 
husbandry, difficult in utero manipulation, and are unamenable to high throughput screening 
[61]. The zebrafish (Danio rerio) provides an alternative model to overcome these limitations [59]. 
 Since being introduced for biomedical research purposes by Streisinger et al. in 1981, 
the zebrafish model has taken the place of more complex vertebrates in several disciplines such 
as genetics, developmental biology, and pharmacology. Zebrafish possess sufficient anatomical 
complexity with physiological and genetic (80-85%) homology to humans, thus allowing 
effective modeling of human diseases and neurobehavioral disorders [59,62]. Although there are 
neuroanatomical differences between zebrafish and humans, comparable features of the CNS 
allow for results to be generalized to mammals. For instance, in zebrafish the majority of 
DAergic neurons are located across the diencephalon with ascending projections to the 
telencephalon, while in mammals the midbrain is the main center for DAergic neurons 
(substantia nigra and VTA) [63,64]. However, previous studies have suggested that zebrafish DA 
neurons in the posterior tuberculum (periventricular nucleus of posterior tuberculum; PVN) can 
be a functional equivalent of the main DAergic pathways in the mammalian brain, representing 
an evolutionarily conserved pathway [47,63,65,66]. Furthermore, the zebrafish CNS uses many 
neurotransmitters found in mammals that are responsible for higher order cognitive function, 
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including GABA, glutamate, DA, norepinephrine, serotonin, histamine, and acetylcholine [67]. 
Although the zebrafish CNS is more simplistic, it is capable of mediating complex behaviors such 
as associative learning and most notably, addiction [68]. The study of addiction using animal 
models, mainly rodents, uses two experimental protocols: the conditioned place preference 
(CPP) paradigm and different protocols of drug self-administration. In contrast with self-
administration behaviors, CPP has been found to differentially assess drug reward and engage 
distinct neuro-pharmacological circuitry [69]. Similar to many rodent behavioral paradigms, CPP 
has been adopted in zebrafish neurobehavioral research [69-72].  
 
Conditioned place preference  
 In general, this procedure is governed by basic Pavlovian principles, in that the incentive 
salience of the treatment serves as the unconditioned stimulus (UCS).  When paired with 
neutral environment stimuli, the UCS acquires secondary motivational properties that induce 
the approach behavior in the absence of the UCS, serving as a conditioned stimuli (CS) [73]. The 
UCS can be virtually any substance that is experienced as rewarding, such as drugs or appetitive 
stimuli, and tactile, spatial, and visual contextual cues can be used as CS. The CPP apparatus 
varies by design, but typically consists of a conditioning box consisting of two or three distinct 
compartments [61,71,72]. The procedure generally consists of three testing phases. During phase 1 
the animal is permitted to explore all compartments of the conditioning apparatus, and the 
time spent in each compartment is quantified and used as a baseline place preference. In phase 
2, animals are restricted to each compartment for a period of time in which they receive either 
experimental or control treatment. In phase 3, the animal is once again allowed access to all 
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compartments and final place preference is measured. Preference for the drug-paired 
compartment is indicative of the rewarding properties of the drug. Based on previous research 
studies, it has become widely accepted that increased dopamine transmission is necessary for 
the establishment of CPP behavior [71-73].  
  
Research Question 
In this work, I address the following question: how does the release of DA mediated by 
psychoactive drugs AMPH and THC influence the expression of D1- and D2-like receptors in the 
addiction phenotype? 
In this study we identify the mechanisms by which two drugs of abuse, AMPH and THC, 
stimulate the mesolimbic reward pathway. We hypothesized that AMPH and THC both activate 
the zebrafish reward pathway but result in differential expression of D1-like vs D2-like 
receptors in various brain regions, more specifically in dopaminergic projections from the 
midbrain paraventricular organ to the hypothalamus. These essential brain areas receive and 
integrate sensory stimuli to drive behaviors related to survival, including feeding, mating, 
migration, and avoidance.  In the following chapters, we detail neuroadaptations influenced by 
the differential expression of D1-like vs D2-like receptors in the zebrafish (Danio rerio) addiction 
model. Given our model organism, measuring addiction based on drug self-administration is not 
feasible, however additional behavioral paradigms, such as CPP, allow for translational 
modeling of addiction.  Specifically, in Chapter 2, we used HPLC to confirm the presence of 
amphetamines in fish brains after drug treatment, then we detailed the various methods we 
used to address our central research question.  Chapter 3 illustrates the interactions between 
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AMPH and THC with conditioned learning behaviors. We also identify unique, drug-specific 
behaviors elicited by fish following treatment and compare those with expected behaviors.  In 
this results chapter, we also determine whether chronic exposure to AMPH differentially 
regulates the expression pattern of dopamine receptors within the zebrafish reward system.  
We used immunofluorescent staining to measure expression of TH, DRD1, and DRD2 in controls 
and AMPH-treated fish.  Finally, in Chapter 4 we discuss the impact of our findings and 
recognize the integrative importance of my study in advancing our understanding of the 
zebrafish as a translational addiction model, and in understanding the evolutionary significance 




























Chapter 2: Materials and Methods 
 
2.1. Animals and Maintenance 
Adult zebrafish of randomly bred genetically heterogeneous ‘wild-type’ strain were obtained from a 
local distributor (Optimum Aquarium, Kennesaw, GA 30144). All fish were acclimated to the laboratory 
environment for a minimum of 10 days, housed in 10-liter (L) aquaria at a density of ~2 fish per 1L, and 
then individually and adjacently housed within 3 L tanks at least 48 hours prior to behavioral testing. 
Zebrafish used in these studies were ~6 months old and maintained in a circulating system equipped 
with biological, chemical and mechanical filtration, aeration, and sterilization by UV light (Pentair 
Aquatic Habitats). Mounted LED lights provided illumination during a 14 h/10 h light/dark cycle. Tank 
water consisted of reverse osmosis deionized H2O with supplemented dissolved sea salts (Instant Ocean) 
and was maintained at ~26-28 Co. Fish were fed twice daily Zeigler zebrafish diet (Pentair Aquatic 
Ecosystems). All animals were drug and experimentally naïve prior to testing. Behavior was recorded by 
USB webcam (saved as WMV files for subsequent analysis) mounted to an overhead shelter, which also 
provided equal light distribution. All protocols for animal use, housing and care were approved and 
carried out according to the Institutional Animal Care and Use Committee of Kennesaw State University. 
 
2.2 Conditioned Place Preference Paradigm 
 
Apparatus.  All experiments were conducted between 9:00 and 14:00 h. Our behavioral tank 
was designed according to Ninkovic and Bally-Cuif [48], with some modifications. The testing tank 
dimension 30 cm in length, 15 cm in width and 20 cm height. Distinct visual cues divided the 
experimental tank into two halves: one half colored white and the other was either white with black 
stripes or white with black dots. Zebrafish did not clearly show a collective preference towards one half 
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of the experimental tank; therefore, it was considered an unbiased tank. Conditioning tanks were 
identical in design, with the exception of a central divider. The water level was kept at 17 cm from the 
bottom of the tank to minimize stress. 
 Pretest: Place Preference (PP) Determination.  After an initial introduction into the testing 
apparatus, each fish was separately accommodated to the new environment for two full days (day 1 and 
day 2). On the third day, fish were carefully netted from their home tanks and placed directly into the 
CPP apparatus. Home tanks of animals were placed in close proximity to experimental tank to minimize 
netting stress and hypoxia. The zebrafish was then permitted to explore the environment for 5 minutes; 
the initial 5 minutes of exploration is designated for acclimation to the environment. Once acclimated, 
behavior was recorded for 10 minutes, after which fish were returned to their housing tank. The 
preferred compartment was defined as the compartment in which a fish spent most of the time on day 
3. This value was then expressed as a percentage, which served as the animals’ baseline side preference. 
 
Conditioning: D-Amphetamine-Induced CPP.  After PP determination, zebrafish were assigned to 
either Group A (control) or Group B (D-amphetamine). Animals assigned to group B received food 
containing 40 µg D-amphetamine on days restricted to non-preferred compartment and control food on 
days restricted to preferred compartment. Zebrafish were fed agarose aliquots in housing tanks 30 
minutes prior to being transferred to the experimental tank. On day 4, zebrafish were confined to the 
non-preferred compartment for 45 min. Restriction to this compartment was achieved using a 
transparent divider such that visual contact to the preferred compartment was possible. The 
experimental tank and conditions were otherwise identical to the ones used for PP determination, and 
each fish was tested alone. After 45 min, the fish was removed from the experimental tank and placed 
back in its housing tank. On day 5, fish were fed control food then restricted for 45 min into the 
preferred compartment. Restriction to the non-preferred compartment was repeated on days 6, 8, and 
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10 and restriction to preferred compartment repeated on days 7 and 9. PP was then measured again on 
day 11.  
  Conditioning: Δ9-tetrahydrocannabinol (THC) Induced CPP.  After PP determination (day 3), each 
fish was weighed (weights varied between 0.2 and 0.8 g per fish) and assigned to one of three treatment 
groups: control (Group A), vehicle control (Group B), or Δ9-tetrahydrocannabinol (Group C). On day 4, 
zebrafish were sedated (using either 0.01% MS-222 or cold water sedation protocol) then 
intraperitoneally (IP) injected as followed: Group A injected with saline, Group B injected with ethanol, 
and Group C injected with Δ9-tetrahydrocannabinol. To ensure IP delivery of solution, 3 g methylene-
blue per gram body weight in 110 mM NaCl was added as a tracer. Each zebrafish was immediately 
confined to the non-preferred compartment for 45 min. After 45 min, the fish was removed from the 
experimental tank and placed back in the housing tank. On day 5, each fish was injected IP with a saline 
solution, then restricted for 45 min into the preferred compartment. Restriction to the non-preferred 
compartment was repeated on day 6 and restriction to preferred compartment repeated on day 7. PP 
was then measured again on day 8. 
 
Test: Change Place Preference.  Fish were tested for final preference using identical procedures used to 
determine baseline preference on day 1. Final preference testing took place at least 16 h following 
conditioning to ensure that the nervous system was void of any drug. Change in place preference was 
calculated by subtracting the time spent on the drug-paired environment before conditioning from the 
time in the drug-paired environment after conditioning. 
 
2.3 Brain D-Amphetamine Levels 
 
Extraction and determination of D-amphetamine concentration were carried out according to 
the high-performance liquid chromatography (HPLC) protocol developed by Bowyer et al [68]. In this 
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method o-phthaldialdehyde (OPA) in conjunction with the reduced sulfhydryl group, 3-
mercaptopropionic acid (3MA), reacts with primary amines to form fluorescent moieties.   These 
derivatives of D-amphetamine are then measured using HPLC with fluorescence detection. 
Instrumentation – Agilent 1100 series HPLC system comprising an online degasser (G1379), a 
quaternary pump (G1379), thermostated autosampler(G1329A), and a thermostated column 
compartment was used. Detection of fluorescent D-amphetamine derivatives was carried out using an 
Aligent 1100 series diode array detector equipped with a 5L flow cell. Separations were performed 
using a 250 x 4.6 mm C18 column (Kinetex 5 EVO C18 100A), and a guard column containing the same 
phase, both maintained at 4oC during analysis.  
Reagents and solvents –  D-amphetamine, o-phthaldialdehyde, 3-mercaptopropionic acid and 
sodium tetraborate decahydrate was obtained from Sigma. All solutions were prepared from analytical-
grade chemicals (Fischer Scientific), dissolved in Milli-Q water and HPLC-grade solvents. 
Collection of brain samples – Subjects (n=10) were fed 10 L aliquot amphetamine spiked food 
and sacrificed at varying time points post consumption (30, 45, 60 minutes). Brains were quickly 
removed from the skull and dissected on a chilled glass plate. Samples of brain tissue were also collected 
from untreated fish (n=4) for blanks and standards. All samples were stored at -80oC until analysis.  
Preparation of OPA reagent – For fluorescence detection 27mg OPA was dissolved in 500L 
ethanol, 5mL of 0.1 borate buffer (pH 9.6) and 40L of 3-MA. This mixture was kept refrigerated and 
discarded after 48 hours. 
 Sample preparation and extraction – Brain samples were pooled for each time point, weighed 
and diluted with 9 volumes of 0.1M borate buffer (pH 10.6). After 20s of ultra-sonication, samples were 
centrifuged for 10 min at 18000g. 100L of the supernatant was transferred to clean centrifuge tube 
and 200L of ethyl acetate was added. The mixture was vortex-mixed for 2 min and placed on ice. After 
10 min on ice an additional 200L ethyl acetate and 200L of water were added to the mixture followed 
by brief vortex-mixing to further facilitate extraction. Centrifugation for 10 min at 18000g was used to 
separate the organic and aqueous phases. Then 200L of the organic supernatant was transferred to a 
glass tube and dried at 45oC under nitrogen. Samples were reconstituted in 80L KH2PO4 (0.05 M, 
adjusted to pH 2.6 with phosphoric acid). After adding 20L of borate buffer (adjusted to pH 11.5 with 
sodium hydroxide) all samples were derivatized with 20L OPA reagent. OPA reagent was added to each 
sample at least 2 min before injection. Derivatization was performed in capped Eppendorf tubes which 
were kept at 4oC until injection.  
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 HPLC conditions – A linear gradient program (Table 2) was run at ambient temperature with 
mobile phase A consisting of 65% KH2PO4 (0.05 M, adjusted to pH 5.5 with potassium hydroxide) and 
35% methanol, and mobile phase B with inverse proportions of buffer (35%) and methanol (65%). 
Fluorescent detector settings were: excitation 340 nm, emission 440 nm. Linear equation was calibrated 
with standard amphetamine solutions prepared at three different concentrations (2.5, 5.0 and 10 M) in 
microdialysis buffer. Calibration curves were constructed by plotting the peak areas of OPA-3-MA-
amphetamine (y, mAU) against the concentration (x, M). 
 








Buffer A (%) 
 
Buffer B (%) 
Initial (0) 1.5 100 0 
0-3 1.5 100 0 
4 1.5 0 100 
18 1.5 0 100 
 
 
2.4 Locomotor activity assay in a novel environment 
To measure zebrafish locomotor activity, individual zebrafish were weighed (weights varied 
between 0.4 and 1.1 g per fish), injected IP and placed in a transparent tank with dimensions 21.5 cm 
long, 10.1 cm wide and 12.5 cm high, filled with 1.5 L of system water. A camera, placed 1 m in front of 
the tank, started recording 10 min after the fish was placed in the chamber. Recording time was 10 min 
at 25 frames per second (fps). Subsequent video clips were analyzed using behavioral tracking software 
(AnyMaze). The locomotor activity was scored based on distance traveled in cm (activity) and time spent 
in the “safe” bottom portion of the tank and in the “risky” top portion of tank (vigilance). Drugs and 
dosages were as followed: D-amphetamine (40µg/g IP), DRD1 agonist SKF 81297 (0.3µg/g IP), and DRD2 
agonist Quinpirole HCl (0.3µg/g IP).  Drug exposure was repeated every day for four days, and 




2.5 Statistical Analysis 
 IPP vs. CPP.  For each individual, initial place preference was identified and calculated as the 
difference in time spent in the preferred versus the non-preferred tank side.  Following the conditioning 
paradigm, the differences between preferred and non-preferred tank were determined, depending on 
the initial preferred side for each fish.  The differences in IPP and CPP for each fish in each treatment 
group were analyzed with an F-Test to compare for variances within treatments.  Once equal variance 
was determined, we compared IPP time differences to CPP time differences with two-tailed Paired T-
Tests using Graph Pad Statistical Software (Prism).  For each analysis p < 0.05, and error was measured 
using standard error of the mean (SEM).  Table 3 below lists the treatment groups and the number of 
samples per group (n). 
 Locomotor Assay.  For these experiments, locomotor activity parameters (distance traveled, 
time at top or bottom of the tank, and other behaviors) were measured then compared at day 1 of 
treatment and day 4 of treatment to recognize the effects of these drugs on locomotor behavior and 
vigilance.  Like the IPP vs. CPP experiment, the time the fish spends at the “risky” top region of the tank 
is subtracted from the time spent at the “safer” bottom region of the tank.  These differences are 
compared between day 1 and day 4 of treatment using T-tests (p < 0.05, and error was measured using 
SEM).  Total distance traveled for each treatment was also compared at day 1 and day 4 also using T-
tests to assess effects of the drugs on activity. Table 3 below lists the treatments and the number of fish 








Table 3.  Behavioral Assay Treatment Groups 
IPP vs CPP Treatments n Locomotor Assay Treatments n 
Control agarose fed 13 Control cold water anesthetized 8 
Amphetamine agarose fed 20 Amphetamine cold water anesthetized 8 
Control MS222 anesthetized 24 SKF 81297  
DRD1 agonist 
8 
THC MS222 anesthetized 28 
Control cold water anesthetized 8 Quinopirole HCl 
DRD2 agonist 
8 
THC cold water anesthetized 12 
 
2.6 Immunohistochemistry and Microscopy 
 The fish were anesthetized with 0.1% MS-222. Brains were dissected and fixed in 4% 
paraformaldehyde at 4oC overnight. Fixed brains were then washed three times for 10 min with 1xPBS 
and then transferred into a solution of 30% sucrose in PBS (w/v) overnight or until tissue sinks. On the 
next day, cryoprotected brains were transferred to Tissue-Tek O.C.T, froze using dry-ice chilled 
isopentane and maintained in -80oC freezer until processing. Transverse sections through 
mesencephalon region of brain were taken at 20 µm and collected on charged slides. 
 Immunofluorescent staining for DRD1, DRD2, and TH.  Tissues were double-stained using an 
immunohistochemistry procedure previously optimized to show expression of TH, DRD1, or DRD2 
throughout the mesencephalon (Ganser et. al., 2013). For TH expression, mouse anti-TH1 monoclonal 
antibody, (Immunostar) was applied at a concentration of 1:500, then counterstained with super clonal 
Alexa Fluor 488 goat anti-mouse secondary antibody (Invitrogen, green) at 1:500 (2ng/µL). DRD1 
expression was highlighted with a 1:500 dilution (0.334 ng/µL) of rabbit anti-DRD1 monoclonal antibody 
(Abcam) and labeled with Alexa Fluor 568 goat anti-rabbit secondary antibody at 1:500 (6 ng/µL) 
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(Molecular Probes, red). Rabbit anti-DRD2 polyclonal antibody applied at 1:500 (6ng/µL) (Immunostar), 
counterstained with Alexa Fluor 568 goat anti-rabbit secondary antibody 1:500 (6ng/µL) (Molecular 
probes, red) labeled expression of DRD2 in zebrafish brain. 
Completed slides were observed using a Zeiss LSM 700 laser scanning confocal microscope. 3 – 4 
repeated trials were used for each treatment with 6-10 tissue-sections per slide. Pictures were captured 
of each cross section using identical settings (master gain: 756, laser intensity: 6.0 %, pinhole 45 µm, 
digital gain: 1.0) with a z-stack of each tissue-section. Average expression was in the form of 
fluorescence arbitrary units (F. A. U.) for DRD1 (555 channel) stains and were scored by manually circling 
the region of interest (periventricular nucleus of the hypothalamus (PVN)) on each cross section with 
open-source software Fiji. A negative control stain was prepared with the absence of the primary 































Chapter 3:  Results 
Amphetamine Concentrations in the Brain. 
 Fish were euthanized at various time points following amphetamine exposure, brains were 
dissected and analyzed using HPLC for amphetamine presence and represented as average 
concentration obtained within each group (Table 3).  Chromatograms in Figure 5 detail the presence of 
amphetamines (peaks demarcated with an asterisk (*) in treated fish at 30 min (pooled n=3), 45 min 
(pooled n=4), and 60 minutes (pooled n=3) after exposure.  Peaks detected much earlier than 
amphetamine on the chromatograms, indicate the presence of nonspecific biological amines from 
reagent and brain tissue. The relative standard deviation (RSD) for retention time of amphetamine 
derivative within the column was <7.3% and had an average of 5%. Thus, indicating an acceptable level 
of precision for the identification of amphetamine derivative in analyte sample.    
 
 








Average amount d-amphetamine in 
brain tissue 
Control  n=4  0 0 
30 min amph fed  n=3  40g 30.15g 
45 min amph fed  n=4  40g 44.8g 
60  min amph fed  n=3  40g 42.6g 
 








Figure 5. HPLC chromatogram of brain tissue analytes of OPA-3-MA derivatives. (A)OPA-3-MA in 
microdialysis buffer (n=2), (B) Control brain tissue (n=4), (C) d-amphetamine standard (10 M), (D) brain 
tissue 30 min post ingestion of amphetamine food (n=3), (E) brain tissue 45 min post ingestion of 
amphetamine food (n=4), (F) brain tissue 60 min post ingestion of amphetamine food (n=3). * 
represents d-amphetamine-OPA-3-MA derivative. Additional peaks represent unknown amounts of 
other biological amines contained in reagent and brain tissues that peaked much earlier than 

































































 IPP vs. CPP.  Experiences with various stimuli condition our responses to increase the likelihood 
of survival.   Learned responses drive our motivation to seek stimuli that are rewarding and improve 
fitness and to avoid dangerous stimuli.  Dopaminergic neuronal circuits underlie conditioned learning 
and the physiological motivation behaviors for self preservation.  Zebrafish learn behaviors through a 
Pavlovian Condition Place Preference Paradigm (CPP) for which the fish is exposed to an environment 
split between visually unique patterns.  In the present study, fish chose between an all white 
environment, and an all white environment with black stripes.  Fish generally prefer the striped 
compartment, most likely because the black stripes give the illusion of safe cover.  In the present study, 
however, I allowed the fish to determine initial preference (IPP) and used this IPP to set CPP.  For each 
treatment group, I calculated the difference between time spent in the preferred side and the non-
preferred side at IPP then CPP, then compared the differences at these two time points using paired T-
Tests. 
 Amphetamine.  Controls (n=13) and amphetamine-treated fish (n=20) were subjected to the CPP 
paradigm, and differences in time spent in preferred versus non-preferred compartments were 
calculated for fish in each treatment at both IPP and CPP (Figure 6).  Control fish showed no difference in 
place preference between IPP and CPP (p = 0.2549,  = 0.05, t = 1.196, df = 12).  Amphetamine 
treatment, however, did demonstrate a significant associative effect on place preference in IPP versus 
CPP (p = 0.0031,  = 0.05, t = 3.388, df = 19), with subjects showing no preference for the preferred 












Figure 6.  Average differences in time spent between preferred and non preferred sides of the tank were 
measured at Initial Place Preference (IPP) and compared to the average differences in time after 
Conditioned Place Preference (CPP) using T-Tests.  A.) Controls showed no significant difference 
between IPP and CPP (p = 0.2549,  < 0.05, n = 13). B.) Amphetamine exposed fish, however, displayed a 
significant difference between IPP and CPP (p = 0.0031,  < 0.05, n = 20), indicating addiction-like 
behaviors with preference change. 
 
THC and MS222.  When designing the drug delivery methods for this study, I consulted an oft 
cited and frequently followed protocol for CPP in zebrafish involving the use of the common aquatic 
animal anesthetic, tricaine methanesulfonate (MS222) to anesthetized the fish enough that 
intraperitoneal injections of the drug or with vehicle control and sham injections could be done without 
stressing the fish enough to confound conditioned learning response [72].  Behavioral monitoring and 
statistical analyses of control fish anesthetized in MS222 and fish injected with THC after being 
anesthetized, suggested an interaction between MS222 and conditioned place preference.   Figure 7 
shows the results following the CPP paradigm for the group of sham and vehicle injected control fish 
anesthetized with MS222 (C-MS222) and THC injected fish anesthetized with MS222 (THC-MS222) 
A.   B.   
Figure 6.  Time Differences in IPP vs CPP 
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during the protocol.  For controls anesthetized in MS222, time spent in the preferred compartment was 
significantly different at IPP compared to CPP (p = 0.0290,  = 0.05, t = 2.33, df = 23), suggesting MS222 
influences place preference.   Likewise, for MS222 anesthetized, THC-treated fish, time spent in the 
preferred compartment was significantly different at IPP compared to CPP (p = 0.0392,  = 0.05, t = 
2.168, df = 27). The results from this experiment suggest that using MS222 as an anesthetic could be 
causing conflicting results as compared to other methods; therefore, alternative methods for 





Figure 7.  Average differences in time spent between preferred and non-preferred sides of the tank were 
measured at Initial Place Preference (IPP) and compared to the average differences in time after 
Conditioned Place Preference (CPP) with T-tests. A.) Controls anesthetized in tricaine methanesulfonate 
(MS-222) showed a significant difference between IPP and CPP (p = 0.0290,  < 0.05, n = 12), suggesting 
that MS-222 may have an effect on place preference in treated fish.  THC exposed fish that were 
anesthetized in MS-222 also showed significant difference between IPP and CPP (p = 0.0392,  < 0.05, n 
= 28), confounding whether the changes in preference were due to MS-222 or THC 
 
 
A.   B.   
Figure 7.  Time Differences in IPP vs CPP 




THC and cold water anesthetization.  Because our data indicated MS-222 having independent 
effects on conditioned learning, we used a chemical free anesthetizing process. After using cold water as 
an anesthetic, control fish displayed no difference in place preference, even after conditioning (p = 
0.7491,  = 0.05, t = 0.3348, df = 7), suggesting that temperature anesthetization does not influence 
CPP.  However, cold water anesthetized fish that were injected with THC during the conditioning 
protocol displayed a significant change in place preference to the non-preferred compartment after THC 
was introduced in the non-preferred side during conditioning (p = 0.0393,  = 0.05, t = 2.338, df = 11).  
Figure 9 details the average difference between time spent on the preferred side of the tank and the 






Figure 8.  Average differences in time spent between preferred and non preferred sides of the tank were 
measured at Initial Place Preference (IPP) and compared to the average differences in time after 
Conditioned Place Preference (CPP) with T-tests. A.) Controls anesthetized in cold water did not display 
a significant difference between IPP and CPP (p = 0.7491,  < 0.05, n = 8), suggesting that temperature 
based anesthetization likely does not interact with place preference. THC exposed fish that were also 
anesthetized in cold water, though, exhibited a significant difference in place preference after THC 
treatment (p = 0.0393,  < 0.05, n = 12).   
 
 
A.   B.   
Figure 8.  Time Differences in IPP vs CPP 
THC – Cold Water 
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 Locomotor Assays.  Controls.  Fish (n=8) were injected with one of four treatments over a four-
day period, to assay the drugs’ effects on distance traveled (locomotor activity) and water level 
preference (vigilance).  In sham-injected controls, there was no difference in distance traveled (p = 
0.9975,  = 0.05, t = 0.003266, df = 7) or water level preference (p = 0.9768,  = 0.05, t = 0.03019, df = 7) 





Figure 9. A.) Activity in control fish was measured in distance traveled during the 10-minute observation 
period on day 1 and compared to distance traveled on day 4.  Controls did not exhibit a significant 
difference in activity (p = 0.9975,  < 0.05, t = 0.003266, n=8).  B) Vigilance, or the time spent in the 
“safe” bottom level of the tank versus the “risky” top part of the tank, was also not significantly different 




 Amphetamine.  Fish were given I.P injection of d-amphetamine (n=8) at 40g per gram weight 
during the locomotor assay and showed changes in behavior after several days of exposure (Figure 10).  
Specifically, amphetamine-treated fish had an increase in activity at day 4 compared to day 1.  The 
distance traveled increased recognizably, but was not significant (p = 0.0592,  = 0.05, t = 2.25, df = 7), 
nor was vigilance significant between days 1 and 4 (p = 0.8076,  = 0.05, t = 0.253, df = 7).  
A.   B.   
Figure 9.  Control: 









Figure 10. A.) Activity in fish on the amphetamines was measured in distance traveled during the 10-
minute observation period on day 1 and compared to distance traveled on day 4.  Though exhibiting an 
obvious increase in activity by day 4, amphetamine fish did not display a significant difference in activity 
(p = 0.0592,  < 0.05, t = 2.25, n=8), suggesting that a larger sample size may show significance in activity 
by day 4 of treatment.  B) Vigilance, or the time spent in the “safe” bottom level of the tank versus the 




Additional behaviors exhibited by treated fish were unique to amphetamine. Thigmotaxis, a 
behavior associated with habituation, or initial fear and vigilance within a new environment, usually 
decreases in zebrafish over the first few minutes in a new tank48.  Thigmotactic behavior begins when 
the fish is placed in a novel environment, and immediately swims to the lower and safer part of the tank 
along the walls.  The fish explores the tank along the walls until it habituates to the new environment, 
and the perceived stress of threats eases.  Thigmotaxis ends when the fish swims away from the walls 
and explores the middle and more shallow depths of the tank.  Both control and amphetamine treated 
fish exhibited thigmotaxis, though amphetamine treated fish displayed more exaggerated forms of 
thigmotaxis, anxiety behavior and home base behavior.  Anxiety behavior, includes a suite of behaviors, 
A.   B.   
Figure 10.  Amphetamines:   
Activity and Vigilance 
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including exaggerated swimming behavior (darting), diving, scototaxis (natural preference for darker 
parts of the tank), and episodes of freezing75.  Anxiety behaviors were consistently displayed in both the 
CPP behavioral studies, as well as the novel environment/locomotor behavior studies (videos links 
available in supplemental data).  Finally, another type of thigmotactic-related anxiety behavior uniquely 
observed in amphetamine treated fish was home base establishment behavior.  Fish exhibit home base 
behavior when fear and stress do not completely subside, manifesting in short bursts of exploration and 
return to an established safe part of the tank75.  Amphetamine treated fish in both behavioral 
experiments established home base territories, while never fully habituating to the experimental 
environments (videos links available in supplemental data). 
 SKF 81297 DRD1 Agonist.  In the zebrafish, the areas of the brain similar to mammalian brain 
areas that express DRD1-like receptors include associative learning areas and midbrain regions that 
drive motivational behaviors, like the habenula, diencephalon, and midbrain. Compared to DRD2-like 
receptors that are most concentrated in the striatal projections between the midbrain and 
hypothalamus, DRD1 receptors are diffusely expressed from forebrain to hindbrain. These regions are 
associated with reward and pleasure, as well as activating motivation and memory associated with 
learning. As such, we expect that locomotor activity would increase with DRD1 agonist treatment.  
Figure 11 illustrates, however, that there was not a significant difference in activity after four days’ 
treatment (p = 0.3451,  < 0.05, t = 1.012, df = 7), but there was a significant decrease in vigilance by the 






















Figure 11.  A.) Fish treated with the DRD1 agonist, SKF 81297 did not display a significant difference in 
activity at day 1 compared to day 4 (p = 0.3451,  < 0.05, t = 1.012, n=8).  B) Vigilance, or the time spent 
in the “safe” bottom level of the tank versus the “risky” top part of the tank, however, was significantly 




During the locomotor behavior experiments, DRD1 agonist treated fish commonly and uniquely 
displayed akinetic behaviors indicating brain-wide locomotor deficiencies resulting in hypolocomotion75.  
Though measured activity did not decrease significantly after SKF 81297 exposure, fish spent much less 
time in the upper parts of the tank, likely indicating deficits in locomotion.  In particular, DRD1-agonist 
treated fish exhibited “droopy tail” specific akinesia.   While the fish swims, tail movement briefly ceases 
and the tail end of the fish dips down and must physically be corrected.  In extreme cases, the droopy 
tail led to inclined swimming (videos links available in supplemental data). 
 Quinpirole HCl DRD2 Agonist.  DRD2 receptors are heavily expressed in dopaminergic 
projections between the midbrain and hypothalamic areas, suggesting heavy influence on the 
A.   B.   
Figure 11.  DRD1 Agonist SKF 81297:   
Activity and Vigilance 
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communication of other neurotransmitter pathways that influence dopaminergic signaling.  Figure 12 
shows that fish treated with Quinpirole HCl (n=8) did not show significant differences in activity or 
vigilance between days 1 and 4.  Distance traveled was not significantly different at day 1 compared to 
day 4 (p = 0.3658,  = 0.05, t = 0.967, df = 7).  Likewise, vigilance was not significantly different at day 4 






Figure 12.  A.) Fish treated with the DRD2 agonist, Quinpirole did not display a significant difference in 
distance traveled at day 1 compared to day 4 (p = 0.3658,  < 0.05, t = 0.967, n=8).  B) Vigilance, or the 
time spent in the “safe” bottom level of the tank versus the “risky” top part of the tank was also not 
significantly different at day 4 versus 1 (p = 0.8231,  = 0.05, t = 0.2321, n=8). 
 
Though no significant differences in locomotion were measured in DRD2-agonist treated fish, 
these fish exhibited extreme anxiety behaviors.  Like all fish in these behavioral experiments, initial 
placement in a novel environment elicits thigmotaxis eventually subsiding within two minutes after 
placement. Quinopirole HCl-exposed fish, however, exhibited hyperbolic anxiety behaviors that did not 
A.   B.   
Figure 12.  DRD2 Agonist Quinpirole HCl: 
Activity and Vigilance 
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subside throughout the experimental period.  Fish behavior alternated between episodes of freezing 
and darting, along with diving to lower parts of the tank (videos links available in supplemental data).   
 Behavioral assays indicated that drugs of abuse interact with conditioned or associative 
learning.  Though the acute locomotor assays did not yield many significant differences, these 
behavioral recordings did reveal many unique behaviors that were common to particular drugs and call 
into question the differential behavioral phenotypes resulting from stimulation of DRD1 versus DRD2 
receptors in the reward system.   
 
 
Immunofluorescent Mapping of Dopaminergically Active Brain Areas. 
 Control.  Dopamine receptors in the zebrafish are categorized into two main classes. Type 1 
receptors (DRD1, DRD5), after binding dopamine, upregulate cyclic AMP mechanisms and stimulate the 
neuron33.  Potentiation of DRD1 is necessary for cognitive processes, including learning, memory, and 
locomotor responses, and also mediate DRD2 expression30,31. Conversely, type 2 receptors (DRD2, DRD3, 
DRD4), down-regulate cyclic AMP activity, thus help govern regulatory processes involving dopaminergic 
signaling in response to non-novel or non-life threatening stimuli.  Genes encoding dopamine receptors 
(D1 and D2) have been identified and localized primarily in the midbrain and diencephalic regions of the 
zebrafish brain, specifically the tuberculum (projections from the midbrain to the thalamus and 
hypothalamus that mirror the striatal projections in mammals that govern motivational locomotion in 
the nigrostriatal, mesolimbic, and mesocortical reward system projections), paraventricular organ and 
periventricular thalamic nuclei extensions (orthologous to mammalian ventral tegmental area), and 
midbrain association cortices for sensory inputs77. Dopaminergic signaling in zebrafish brain has been 
confirmed through immunocytochemical labeling methods with TH primary antibodies to illustrate CNS 
areas where dopamine is synthesized, and antibodies against DAT, to label dopamine-specific, reuptake 
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proteins involved in signaling among reward system neurons.  Never before, however, have studies 
successfully identified specific dopamine receptor proteins within the zebrafish reward system.  In the 
present study, the brains of control and amphetamine-treated fish were prepared for 
immunofluorescence study, specifically to identify areas of TH expression, as well as the presence of 
DRD1.   
Figure 13 shows an illustrated anatomical atlas of a transverse section through a control 
zebrafish midbrain (Figure 13A-B).  Referencing Figure 13B, Figures 13C (20x) details areas in the control 
zebrafish midbrain where TH is expressed (green). The highest concentration of TH staining was most 
reliably found in this midbrain area where tegmental (RT) and tubercular nuclei (TPp), along with the 
paraventricular organ (PVO), and caudal hypothalamic nuclei (HC, Hd) project anteriorly to the 
hypothalamus (H) and infundibulo-pituitary regions of the diencephalon.   Figure 13D (40x) details the 
regions of the medial midbrain, focusing on the large, TH-labeled somata occupying hypothalamic nuclei 
and the paraventricular organ.  Recall that TH catalyzes the conversion of tyrosine to L-Dopa, the initial 
rate limiting step in dopamine synthesis, and can indicate brain areas where DA signaling takes place.  
The presence of TH, however, could also indicate the presence of other catecholaminergic 
neurotransmitters, like epinephrine (EPI) and norepinephrine (NEPI).  Once L-Dopa is converted to DA by 
aromatic amino acid decarboxylase (AADC), DA itself serves as the precursor molecule to EPI and NEPI. 
TH, therefore, cannot be used as a specific marker of DA, but rather a general marker of catecholamines.  
In the present study, DRD1 serves as the specific indicator of DA signaling in the zebrafish brain. In 
Figure 13E (20x), DRD1 expression (red) in control fish is sparsely present in several areas that parallel 
TH staining, the vascular lacunae of the area postrema (Vas) near the tectal ventricular space, the 
posterior commissure (Cpost), the rostral tegmental nucleus (RT), the paraventricular organ (PVO), and 
three hypothalamic nuclei:  the periventricular nucleus of the posterior tubercle (TPp), the posterior 
tuberal nucleus (PTN), and the dorsal zone of the periventricular nucleus (Hd).  Punctae labeling DRD1 in 
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controls appear to surround mostly smaller cell bodied neurons, compared to neurons labeled with TH-
labeled where green punctae representing TH expression, are found in the cytoplasm of neurons with 
small somata and large cell-bodied neurons with elongate extensions. In Figures 13F-H, DRD1 labeling 
(red) brightly stains midbrain sections of zebrafish treated with amphetamine.  Figure 13F, in particular, 
shows highly concentrated punctae representing DRD1 expression surrounding small somata in the Vas.  
Compared to controls, DRD1 is heavily expressed in the Vas and also concentrated in the TPp, PTN, and 
PVO, while larger cell bodies and extensions present in the Hd are also more heavily stained in 
amphetamine-treated fish and nearly absent in controls.  Magnified (40x) amphetamine-treated fish 
show specific labeling of DRD1 on large somata located in the TPp, PTN, and PVO (Figure 13G).  Finally 
Figure 13H shows heavy DRD1 labeling in the mibrain of another amphetamine-exposed fish in the Vas 
and medial hypothalamic nuclei, but diffuse punctae are also visible in anteriorly projecting tracts in the 
















Figure 13.  Midbrain Dopamine Signaling in 



















Total DRD1 expression was measured by quantifying total fluorescent arbitrary units (F.A.U.) in 
four specific midbrain areas where DRD1 was visualized in both controls and amphetamine-treated fish.  
Representative cross sections of the midbrain region at the level of the corpora quadrigemina and the 
caudal hypothalamus (as in Figure 13A), show the specific areas in Figure 14A, C (control) and Figure 
14B, D (amphetamine) where DRD1 expression was measured.  These areas are summarized (14E), and 
histograms (14F) detail the measured differences in DRD1 expression in each midbrain area for controls 
Figure 13. A) Illustration of a lateral view of the zebrafish brain, highlighting the midbrain area 
represented in the atlas of a transverse section in B.  Representative midbrain nuclei in B serve as 
reference to identify areas where dopaminergic signaling is labeled through immunofluorescence.  In 
B-H, several groups of nuclei or tracts are repeatedly show expression of TH or DRD1, representing 
dopaminergic signaling areas in the midbrain.  From dorsal to ventral, these areas include: the vascular 
lacunae of the area postrema (Vas) found on the ventromedial portions of the tectal ventricle.  Areas 
lateral to the Vas project anteriorly along the posterior commissure (Cpost) and Solitary Tract (ST).  
Other anterior projections that lie ventromedially to the Cpost and ST include the horizontal 
commissure (Chor), Tegmental (Teg) nuclei including the Rostral Tegmental Nucleus (RT) projecting to 
the striatal areas, Posterior Thalamic nucleus (P). Tubercular nuclei like the Posterior tuberculum of the 
medial PreGlomerular nucleus (PGm), Periventricular nucleus of the posterior Tubercle (TPp), the 
Paraventricular Organ (PVO), and several Hypothalamic nuclei: Caudal zone of the Periventricular 
nucleus (Hc), and the Dorsal zone of the Periventricular nucleus (Hd).  In C, control midbrain is stained 
with primary antibody against tyrosine hydroxylase (TH). All of the areas mentioned above showed 
expression of TH in the control zebrafish midbrain, with cytoplasmic punctae identified in neurons with 
large somata (white arrowheads).  Figure D shows a 40x magnified image of the ventromedial midbrain 
portion of a TH-labeled control zebrafish, heavily stained neurons with large somata in the TPp, PVO, 
PVN area.  In E, DRD1 antibody was used to determine which of these TH-labeled areas of the midbrain 
were DA specific.  DRD1 punctae (red) surrounded cell bodies in the Vas, ST, PVN, and Hd.  
Amphetamine-treated fish (F-H) that were stained with DRD1 showed strong labeling, especially in the 
Vas, TPp, PVO, and PVN, and also the Hd (arrows).  These areas are similar to controls, but staining is 
comparatively stronger and heavily concentrated in those areas.  Magnified ventromedial area of an 
amphetamine treated fish brain shows very specific labeling of large cell bodied neurons in the TPp 
PVO, and PVN.  Figure H shows another amphetamine-treated fish midbrain with strong DRD1 labeling 
in the medial areas of the midbrain, and diffuse labeling throughout the anterior projecting areas, 
including the ST, Tegmental, Thalamic, and Tubercular nuclei, and Hypothalamic nuclei.  Other 
abbreviations:  Anterior (A), Cerebellum (Cb), Dorsal (D), Habenula (Ha), Lateral (L), Olfactory Bulb (OB), 
Optic Tectum (OT), Telencephalon (Tel), Torus Semicircularis (TS), and Ventral (V). 
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and amphetamine-treated fish.  Amphetamine-exposed fish showed greater DRD1 expression in all four 
areas compared to controls.  
Because staining confirms the presence of hypertrophied dopamine-specific signaling in 
pertinent midbrain areas, we can draw conclusions that justify behavioral anomalies associated with 
drug exposure and how these particular stimuli can hijack the reward system in organisms whose 






Figure 14.  DRD1 expression was measured in four different midbrain regions to compare expression in 
controls and amphetamine-exposed fish.  Total expression was measured by setting standard gain and 
intensity for DRD1 (555 red) channel and DAPI (405 blue) channel, based on control sections, and 
recording signal intensity in fluorescence arbitrary units (F.A.U.).  Expression was manually scored by 
encircling the same areas of interest in each slide and taking the average F.A.U. for controls (n=4) and 
fish treated with amphetamine (n=8).  A) Control midbrain (20x) showing areas where DRD1 expression 
was measured.  Left dorsal zone of the hypothalamic periventricular nucleus (Hd), Left rostral tegmental 
nucleus (RT), Periventricular nucleus of the posterior tubercle of the hypothalamus (TPp).  B) 
Amphetamine-treated midbrain (20x) showing the same areas where DRD1 expression was measured:  
Hd, RT, TPp.  C) Control dorsal midbrain (20x) showing the right vascular lacunae of the area postrema 
(Vas) where DRD1 was measured and compared to D) the right Vas area in amphetamine-exposed fish.  



















































E) Histogram shows total DRD1 expression per midbrain area in controls versus amphetamines.  F) 
Expression of DRD1 in total F.A.U. is detailed in this table for each region selected in the midbrain. 
 
Chapter 4:  Discussion 
 Communication across dopaminergic circuits in the brain underlies our basal physiological 
motivators that drive survival.  Whether we seek nourishment, companionship, accomplishment, or 
avoid situations that risk our well-being, the neurons governing these behaviors and the genes that 
encode these pathways have not evolved much further than their protochordate roots47,78.  
Phylogenetic analyses show that the enzymes that catalyze various steps in catecholamine synthesis 
(TH, AADC) are present in protostomes, urochordate taxa that far predate the divergence of chordates47.  
Likewise, genes that encode catecholaminergic signaling proteins (vMAT) are present in urochordates, 
while genes for dopamine-specific signaling (DAT) have not been confirmed in taxa more primitive than 
teleost fish47.  Other dopamine-specific signaling molecules, aside from vesicle packaging proteins and 
synaptic transporters, are dopamine receptors, which fall into two categories, Type 1, or D1-like, and 
Type 2, or D2-like78.  Like DAT and vMAT, these two DA receptor categories emerged with bony fish (for 
which there was a genome duplication resulting in eight known receptor subtypes), for which five 
subtypes are functional in the human reward system77.  D1-like receptors (DRD1, DRD5) activate cyclic 
AMP to stimulate dopamine release and signaling, and D2-like receptors (DRD2, DRD3, and DRD4) that, 
when bound, down regulate dopaminergic signaling and decrease dopamine release77.  Because 
zebrafish hold these genes and signaling mechanisms in common with humans, they serve as an ideal 
translational model to study both evolutionary drivers or motivation, learning, memory, and cognition, 
as well as neuropsychiatric diseases associated with dopaminergic pathways79,80,81. 
 The goals of the present study aimed to add support to the growing utility of zebrafish as 
translational models for human disease, even if the diseases are neurological and cognition-based.  By 
subjecting zebrafish to conditioned learning paradigms, and introducing dopamine signal altering drugs, 
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our study draws parallels to the homologous nature of the neuronal circuits driving associative learning, 
choice, motivation, and vigilance in zebrafish and humans.  Because zebrafish have well-categorized, 
stereotypic behaviors in response to certain stimuli, we can quantify responses, observe novel 
behaviors, and inform on or compare behaviors to humans under similar conditions.  Specifically, 
knowing that zebrafish that exhibit seeking and vigilant behaviors in response to experientially learned 
stimuli, confirm that reward and fear behaviors are heavily conserved as evolutionary motivators of self-
preservation and fitness, along with the neural circuits that mediate these responses, to drive these 
behaviors.  Likewise, the use of addictive amphetamines to demonstrate similarities to human 
amphetamine-induced responses and addictive behaviors, supports the use of zebrafish as translational 
models of addiction and neuropharmaceutical responses.  Our study, however, goes beyond behavioral 
assays to detail neuroplastic changes in dopamine signaling within the zebrafish reward system in 
response to drugs of abuse.  When I initially planned this study, I knew that primary research measured 
amphetamine72 and THC-induced behaviors83,84 in zebrafish.  Some studies also mapped the expression 
of genes, synthesis proteins, or signaling proteins in the brain related to drug exposure in 
zebrafish48,77,79,80.  None of these studies, however, were able to correlate amphetamine-induced 
behavioral changes with dopamine receptor-specific signaling in the zebrafish reward circuit.  The two 
most dominant dopamine receptor subtypes, DRD1 and DRD2, are active and present in the zebrafish 
brain48, and the genes that encode these receptor subtypes have been confirmed in dopaminergic 
signaling pathways through in situ analyses48, 77.  Though the presence of dopamine synthesis (TH) and 
signaling molecules (DAT) has been confirmed and mapped in the zebrafish brain through 
immunohistochemical analyses77, studies that imply dopamine specific signaling because of the 
presence of TH in similar reward type circuits in the zebrafish brain, can only definitively say that the 
presence of TH indicates general synthesis of catecholamines.  Immunolabeling studies utilizing the 
signaling protein, DAT, however, can specify the presence of dopamine-related signaling, thus the goal 
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of my study was to confirm the presence of DRD1 in the zebrafish brain and to map its expression in 
reference to TH expression, and to recognize any differences in DRD1 expression following 
amphetamine exposure.   
 CPP and MS222.  I based my behavioral experimental setups on three seminal zebrafish CPP 
papers59,62,71, that detailed analyses of measurable behaviors.  All studies recommended IP injection of 
study agents, and the protocols for humane anesthetization with tricaine methane sulfate (MS222) for 
brief immobilization and intraperitoneal injection, however the behavioral data measured in 
anesthetized controls indicated that MS222, itself, affected CPP (Figure 7).  MS222, a sodium channel 
blocker with no particular channel specificity, slows neuronal signaling by temporarily blocking sodium 
channels that must open to propagate an action potential.  Because movement of sodium across the 
neuronal membrane affects all neuronal signaling, MS222 was likely influencing dopaminergic signaling 
that affected experiential learning.  The interaction of anesthetic with CPP led us to use non-chemical, 
cold water anesthetization to sedate the fish.  Control fish anesthetized with cold water showed no 
difference in place preference following conditioning, and thus the remainder of our experiments used 
this immobilization protocol to study the effects of amphetamines on behavior.  Though behavioral tests 
assaying the effects of THC on CPP following cold anesthetization were done, the brains of these fish 
were not analyzed. 
 Previous zebrafish CPP studies that used MS222 as an anesthetizing agent may have had 
underlying changes to conditioned behavior that may not be directly correlated with the study 
treatment.  The synergistic effects of drugs tend to compound neurobehavioral disorders as well, and 
emerging reports on the comorbidity of prescribed drugs in veterans with PTSD, details how wounded 
veterans are often prescribed opiate pain killers along with benzodiazepines for their PTSD-related 
anxiety85,86.  The long-term prescription of each of these medications alone significantly increases risky 
behaviors in veterans84. However, as they are often prescribed together, incidents of self-harm, 
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addiction to other substances or behaviors, noncompliance with prescriptions, development of OCD and 
social anxiety, and suicide dramatically increase84,85.  What the zebrafish tells us, in its behavioral 
responses to MS222 apart from THC, is that other stimuli or agents may not only influence dopaminergic 
circuits, but may also make the brain more susceptible to altered signaling. 
 Amphetamine.  Zebrafish in all of our treatment groups responded to CPP as expected, 
specifically, amphetamine-exposed fish spent significantly less time on the initial preferred side after 
conditioning the fish on the nonpreferred side with amphetamine.  Though the differences were not 
significant, in the locomotor assays, the activity, measured in distance traveled, did show an increase 
nearing significance as expected.  Vigilance, measured in time spent on the risky versus safe water levels 
of the tank, was unexpectedly not significantly different following drug exposure.  Amphetamines are 
broadly acting central nervous system stimulants, meaning they upregulate the activity of all the 
excitatory neurotransmitters in the brain (DA, 5HT, NEPI, EPI, and ACh).  Amphetamines specifically 
upregulate dopamine transmission by blocking reuptake of DA by inward rectifying presynaptic 
dopamine transporters, influencing presynaptic pH such that DA does not get packaged into vesicles, 
and reversing reuptake transporters such that the cytoplasmic presynaptic dopamine that is unbound by 
vesicles quickly floods the synaptic cleft79.  Because AMPH is a global excitatory neurotransmitter 
agonist, we expected upregulation of activity and increased vigilance due to the upregulation of fight or 
flight neurochemicals.  Though some of our locomotor assays did not show significant upregulation of 
activity, specific behaviors displayed (thigmotaxis, diving, anxiety behaviors) by amphetamine treated 
fish indicate hypertrophied stress.  Thigmotaxis, specifically, a habituation behavior exerted by fish 
exposed to novel environments was more common and exaggerated in amphetamine-exposed fish 
versus control, and likewise in DRD1-agonist treated fish.   
 We expected that amphetamine treated fish would show an increase in DRD1 signaling, because 
its mechanism of action upregulates dopamine transmission into the synapse.  Likewise, because of its 
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stimulatory effects, we expected an increase in DRD1 activity, because the potentiation of DRD1 
receptors upregulates cAMP to stimulate DA signaling.  Behaviors observed, like increased activity and 
anxiety-like behaviors do support the hypothesis that DRD1 signaling would be upregulated in 
amphetamine exposed fish.  Moreover, the influence of amphetamine in place preference strongly 
supports its altering (upregulation) of dopaminergic signaling related to experiential or conditioned 
learning.  Interestingly, the strong labeling of DRD1 expression in the midbrain also suggests that 
amphetamine increases dopaminergic signaling, but primarily in midbrain areas projecting to striatal 
areas governing movement (Tegmentum), thalamic association nuclei (integrating centers for 
appropriate responses to sensory inputs), and hypothalamic projections that mediate motivation, or 
seeking behaviors, conditioned or experiential learning, and fear/startle responses.  Expression of DRD1 
was particularly strong in dorsomedial and medial areas of the midbrain.  Figure 13 shows that DRD1 
expression was centered primarily in the vascular lacunae of the area postrema (Vas).  This particular 
nucleus contains chemosensory neurons that come in contact with heavily fenestrated capillaries that 
likely monitor the blood brain barrier for toxins and osmoregulatory homeostatic cues86.  Though the 
Vas is present in Chondrichthyes and repeatedly labeled and identified in zebrafish brain atlases, its 
specific functions remain a mystery86.  Its presence in early vertebrates and its unique specialization in 
mammals as the chemical trigger zone (CTZ) that mediates vomiting in response to chemical toxins 
detected in the blood, along with its conserved location, anatomy, and stimulation by catecholaminergic 
inputs, suggests a similar function among vertebrates in avoidance.  Morita and Finger (1987)86 did the 
only teleostean study of the Vas in which the anatomy, connectivity, and immunocytochemistry 
confirmed afferent and efferent vagal inputs as well as heavily concentrated TH staining.  In mammals, 
the Vas (CTZ) is also highly vascularized and serves as the body’s safe guard against toxin infiltration.  
When poisons are detected by chemoreceptors in the Vas, DA floods the area inducing immediate 
vomiting86.  Because of its proximity to and innervation by dopaminergic projections involving 
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avoidance, the Vas likely serves as a chemical trigger zone of sorts for zebrafish by inducing escape 
behaviors in response to noxious stimuli.  The Vas heavily expresses DRD1 in both controls, but more so 
in amphetamine-treated fish, suggesting that these fish would likely exhibit more avoidance, stress, and 
vigilance behaviors, though these were not significantly increased in our fish. 
 Several other midbrain regions showed increased DRD1 labeling in amphetamine-treated fish 
versus controls.  We recognize that DRD1 staining in controls and AMPH fish parallels TH staining in 
controls, however, not all areas that showed TH labeling were positive for DRD1 staining, suggesting 
that TH is not a reliable indicator of DA-specific signaling.  Aside from the Vas, though, DRD1 punctae 
were evident in the periventricular nucleus of the posterior tubercle (TPp) a thalamic nucleus, along 
with the periventricular nucleus of the ventral tubercle (PVN), and the paraventricular organ (PVO) are 
thought to mediate DA synthesis for forward projecting connections to hypothalamic areas that govern 
reward-specific behaviors.  DRD1 was also present in the rostral tegmental area (RT), a group of 
projections that mirrors the mammalian striatum for the nigrostriatal dopaminergic pathways 
controlling movement and motivation.  Finally, DRD1 staining was especially strong in the dorsal 
hypothalamic nuclei (Hd), a group of cell bodies whose axons project anteriorly and serve to enable 
physiological drive, motivation, and satiety. Staining was sparse or absent in controls in these areas 
compared to amphetamine-treated fish. 
 Furthermore, for the locomotor behavioral study, we expected that treatment with a DRD1 
agonist would increase activity and vigilance, for the same reasons we thought amphetamine-treated 
fish would show increases in activity and vigilance that would mirror its upregulation of DRD1.  
Triggering of DRD1 stimulates dopaminergic signaling, and though these DRD1 agonist-treated fish 
showed significant differences in vigilance, they did not have an upregulation of activity.  These results 
contrast the increase in activity and absence of change in vigilance behavior in amphetamine fish for 
which we also see increased DRD1 signaling. 
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 THC and CPP.  Our initial THC behavioral studies were confounded by MS222, but we did 
condition several fish with THC using the cold water anesthetization protocol.  THC is known to exert 
secondary effects on dopamine release to trigger reward, however, its initial effects on 
endocannabinoid receptors effectively slow down motor, perception, and cognitive responses through 
second messenger mediated neuronal membrane hyperpolarization82.  We expected reduced activity in 
the THC-treated fish, and these inhibited behaviors in fish were casually observed in reduced episodes of 
locomotion, absolute stillness during thigmotaxis, and the inability to respond to any sort of threatening 
stimuli, even handling.  Aside from its initial inhibitory effects, THC did have a significant effect on CPP 
following treatment, suggesting that its stimulation of DAminergic pathways.  THC is not only desired for 
its calming effects, but it also triggers the dopamine-driven reward system to give feelings of euphoria82.  
Because of these initial inhibitory effects, we expected that THC-treated fish would show an increase in 
DRD2 signaling compared to DRD1, however, none of the brains we stained with DRD2 antibody showed 
any expression.   
 We can, however, draw parallels between DRD2 signaling and inhibitory behaviors.  Though 
treatment with DRD2 agonist did not yield any locomotor behavior anomalies, DRD2-treated fish 
showed hypolocomotor behaviors, like tail dipping, and bouts of slowed or absent locomotion 
consistent with DRD2 stimulation.  The reduction of dopaminergic neuronal activity by the inhibition of 
cAMP by DRD2, should result in reductions of motivators for movement and vigilance.  Though these 
behaviors were not significantly decreased after DRD2 treatment, fish did show behaviors indicative of 
suppression of locomotion. 
 The significance of these combined behavioral and immunofluorescence data suggest that 
zebrafish are a viable model for studying both behavioral and neuroplastic changes brought about by 
drugs of abuse and other dopaminergic circuit-related neuropsychological disorders.  These new 
findings, that DRD1 signaling is specific to the midbrain areas homologous to human dopaminergic 
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circuits and upregulated in amphetamine-treated individuals, invites many new questions regarding the 
differential effects of pharmaceuticals on dopamine signaling and behavior.  By being able to recognize 
stereotypic responses to certain drug classes, and match them with specific DA receptor signaling in 
specific parts of the reward pathway, studies like this will help to inform on targeted treatments for 
addiction, anxiety, and compulsion disorders. 
Integrative Significance.  In recent years, the use of zebrafish to study the behavioral response to 
drugs of abuse has increased providing a rich platform with which to explore how these psychoactive 
drugs influence neurotransmitter systems. All addictive drugs are believed to increase dopamine 
transmission, beginning in the ventral tegmental area (VTA) of the midbrain and innervating the nucleus 
accumbens (NAc), amygdala, hippocampus and prefrontal cortex in humans. Although this mesolimbic 
dopamine system is not conserved among humans and zebrafish, the anatomical organization of the 
nervous system in similar among vertebrates, and the lateral and medial pallium in the zebrafish are 
analogous to the hippocampus and associated mesolimbic circuitry in humans. Dopaminergic receptors 
are expressed throughout these brain regions of vertebrates including zebrafish. Four classes of 
dopaminergic receptors, identified in zebrafish, correspond to the mammalian D1, D2, D3 and D4 
orthologs. Drd1 is the homolog of the mammalian D1-like receptor type, and drd2a, drd2b, drd2c, drd3, 
drd4a, drd4b and drd4c are homologous to the mammalian D2-like receptor type. From the literature 
we conclude that the interaction between dopaminergic signaling, specifically involving stimulation of 
drd1, is implicated in experiential learning and seeking behavior. Addictive behavior, motivated by 
amphetamines and other drugs of abuse, negatively influence the reward system by perpetuating 
reinforced learning towards drug related stimuli. Zebrafish display excellent cognitive abilities and 
complex decision-making, and, like rodents, show robust behavioral responses to stimuli, with high 
sensitivity to pharmacological manipulations [75]. Behavioral paradigms historically tested in rodents, 
such as conditioned place preference, have only recently been applied in zebrafish neurobehavioral 
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research but has already shown to be an excellent candidate for studying the rewarding effects and 
addictive potential of both well-classified and novel compounds. The zebrafish CPP model along with 
identifying differences in drd1 expression will likely increase our understanding of factors contributing to 
the pathogenesis of addiction and subsequently aid in the development of treatment strategies. 
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